Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
G
456160
vs
K
KOSPI 200
Over the past 12 months, G2GBio Inc has underperformed KOSPI 200, delivering a return of +24% compared to KOSPI 200's +116% growth.
Stocks Performance
456160 vs KOSPI 200
Performance Gap
456160 vs KOSPI 200
Performance By Year
456160 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
G2GBio Inc
Glance View
G2GBIO, Inc. is a drug delivery system platform company possessing microsphere source technology InnoLAMP for the development of sustained-release pharmaceuticals. The company is headquartered in Cheongju, Chungcheongbuk-Do and currently employs 48 full-time employees. The company went IPO on 2025-08-14. The firm is mainly engaged in the development of long-acting pharmaceutical products, including pipeline candidates such as GB-7001 (for diabetes and obesity) and GB-5001 (for dementia).